



MEDICAL DEVICES



PHARMACEUTICALS



CHEMICALS



FOOD & BEVERAGE



ELECTRONICS

This report is being updated. Subscribers will receive complimentary copies of the previous edition while the new report is in preparation.

Top 10

World's Leading DIAGNOSTICS Companies

A NEW THOUGHT-PROVOKING REPORT ON PERFORMANCE, CAPABILITIES, GOALS AND STRATEGIES OF THE MAJOR COMPETITORS IN THE WORLDWIDE DIAGNOSTICS MARKET

- Abbott
- Beckman Coulter
- Becton Dickinson
- BioMerieux
- Bio-Rad
- J & J
- Roche
- Siemens
- Sysmex
- Thermo Fisher

Available by Company and Section!

Contains nearly 1,000 pages and 70 tables

Includes a 95-page Worldwide Market Overview

Visit www.vpgcorp.com to review this and over 5,000 reports



VENTURE PLANNING GROUP

WWW.VPGCORP.COM

INFORMATION • INTELLIGENCE • ANALYSIS • INSIGHT

Rationale & Objectives

A strategic assessment of the competitive environment is unquestionably one of the highest priority management responsibilities -crucial to business survival, growth and profitability. Timely and factual competitive intelligence is vital to the success of all business functions, especially Planning, Marketing, R&D and Manufacturing. In a highly dynamic and fragmented in vitro diagnostics market, besieged by intense competition, rapid pace of technological innovations, and the uncertainty regarding future government regulations, the ability to anticipate new competitive product introductions and marketing strategies is particularly important... and can spell the difference between success and failure.

The **Top 10**, a unique series of market intelligence studies first introduced by VENTURE PLANNING GROUP in 1987, is designed to provide the in vitro diagnostics industry executives, as well as companies planning to diversify into the diagnostics field, with strategically significant competitor information, analysis and insight, critical to the

development and implementation of effective R&D and marketing programs. The study's major objectives include:

- To establish a comprehensive, factual and cost-effective information base on performance, capabilities, goals and strategies of the world's leading in vitro diagnostics companies.
- To help current diagnostic product suppliers realistically assess their technological, financial and marketing capabilities vis-a-vis leading competitors.
- To assist potential market entrants in evaluating prospective acquisitions and joint venture candidates.
- To complement organizations' internal competitor information gathering efforts by providing strategic analysis, data interpretation and insight.
- To identify the least competitive market niches with significant growth potential.

Study Content

WORLDWIDE MARKET DYNAMICS AND TRENDS

The study will provide an approximately **55-page** worldwide strategic overview of the in vitro diagnostics market, including the Five-year reagent and instrument sales forecasts for major testing locations (hospitals, commercial/private laboratories, physician offices/group practices, blood centers, personal testing and others) and major laboratory disciplines (blood typing/grouping, chemistry/immunoassay, coagulation, hematology/flow cytometry, histology/cytology, microbiology/serology, urinalysis and others).

Moreover, the five-year worldwide sales projections for the most dynamic market segments, such as molecular diagnostics, infectious diseases, tumor markers, and personal testing will be developed.

In addition, the study will provide a concise review of the major U.S. and international regulatory, economic, demographic and social trends with potentially significant impact on the in vitro diagnostics market during the next five years.

COMPANY STRATEGIC ASSESSMENTS

The following companies have been selected as the **TOP 10** suppliers with the highest worldwide sales of in vitro diagnostic products:

- Abbott
- Beckman Coulter
- Becton Dickinson
- BioMerieux
- Bio-Rad
- Johnson & Johnson
- Roche
- Siemens
- Sysmex
- Thermo Fisher

For each of the **TOP 10** companies, the report will provide an approximately **95-page** strategic analysis, including:

EXECUTIVE SUMMARY

- A 4-7 page synopsis of key sections.

BUSINESS ORGANIZATION

- History of the diagnostics business evolution important to the understanding of the company's corporate culture, management mentality and strategies.
- Most recent significant acquisitions, divestitures and organizational changes.
- Current organizational structure.

SENIOR MANAGEMENT

- Profiles of senior managers.

FACILITIES AND EMPLOYEES

- Major administrative, manufacturing and R&D facilities in the U.S. and abroad.
- Manufacturing practices.
- New plants under construction.
- U.S. and international work force size and distribution.

TECHNOLOGICAL KNOW-HOW

- Internally developed and acquired in vitro diagnostic technologies.
- Know-how in biotechnology, engineering, electronics and other related fields.
- Proprietary technologies and patent litigations.

PRODUCT PORTFOLIO ANALYSIS

- Review of major product lines.
- Specifications, features, advantages, weaknesses, introduction dates and prices of current analyzers, reagent systems and ancillary products.

MARKETING TACTICS

- The U.S. and international sales force.
- Distribution approaches for centralized and decentralized testing markets.
- Healthcare system programs.

- Selling options: reagent plans, leasing, etc.
- Major promotional tactics, e.g., pricing, discounts, advertising, seminars, product literature, newsletters, workflow evaluation etc.
- Instrument service and support.

INSTRUMENT PLACEMENTS AND INSTALLED BASE

- Instrument placements and total installed base in the U.S. and international markets, by analyzer type and model.

SALES AND PROFIT GROWTH

- The Five-year U.S. and international sales and operating profit performance.
- Reagent and instrument revenue by product line and geographic region.

R&D EXPENDITURES AND MAJOR PROGRAMS

- Estimated 2008 diagnostics R&D budget.
- Research facilities and staff.
- New technologies, and products in development, including their specifications, anticipated prices and introduction dates.

COLLABORATIVE ARRANGEMENTS

- Major joint venture, distribution, O.E.M. and licensing partners, both industrial and academic.
- Terms of collaborative agreements and specific products involved.

STRATEGIC DIRECTION

- Specific business, new product development and marketing strategies.
- Anticipated acquisitions, joint ventures and divestitures.

COMPARATIVE ANALYSIS

In this section of the report, the **Top 10** companies will be ranked according to the following criteria:

- Reagent and instrument sales and market shares in the U.S. and abroad.
- Operating profit.
- R&D expenditures.
- Sales force size in the U.S. and abroad.
- Relative technological capabilities and marketing posture.
- Overall strategic position for future growth.

Methodology

INTERVIEWS

The study will be based on interviews with **Top 10** companies' executives, experts from leading medical research centers, customers, joint venture partners, financial analysts, and others knowledgeable of the companies' operations and strategic directions.

INDUSTRY SHOWS

Information gathered from industry shows, marketing conferences and scientific symposia will be also included in the report.

VENTURE PLANNING GROUP'S DATABASE

Venture Planning Group's proprietary data files contain cur-

rent information on major diagnostics companies, technologies, products and executives worldwide, and have been developed in the course of over 100 syndicated and numerous single-client studies. These files will be thoroughly searched to retrieve any information pertinent to the **Top 10** companies' capabilities and strategies.

SECONDARY INFORMATION SOURCES

A comprehensive review of the **Top 10** companies' product and financial literature, business and technical periodicals, marketing and technical meeting presentations, patents, and pertinent industry analyst reports will be conducted.

Cost & Delivery

The cost of local PDF licenses is as follows:

Complete 10-Company Report

Before	After
Feb. 20, 2009	Feb. 20, 2009
\$10,700	\$12,600

Individual Company Assessments

Before	After
Feb. 20, 2009	Feb. 20, 2009
\$1,600 each	\$1,850 each

Subscribers will receive complimentary copies of the previous edition of the report while this study is in preparation.

ORDER FORM

TO: VENTURE PLANNING GROUP

350 Fifth Avenue • Suite 3304 • New York • NY • 10118 tel. 212.564.2838 fax. 212.564.8133 info@vpgcorp.com

I am interested in your new study:

“The Top 10 World’s Leading Diagnostics Companies”

I am interested in a complete 10-company report:

	Before Feb. 20, 2009	After Feb. 20, 2009
<input type="checkbox"/> PDF	\$10,700	\$12,600
<input type="checkbox"/> Print	8,900	10,500
<input type="checkbox"/> Both	13,700	16,200

I am interested in the following individual company assessments:

- Abbott Becton Dickinson Bio-Rad Roche Sysmex
 Beckman Coulter BioMerieux J & J Siemens Thermo Fisher

Cost per company:

	Before Feb. 20, 2009	After Feb. 20, 2009
<input type="checkbox"/> PDF	\$1,600	\$1,850
<input type="checkbox"/> Print	1,350	1,550
<input type="checkbox"/> Both	2,100	2,400

name: _____ title: _____

company: _____

address: _____

city: _____ state: _____

zip: _____ country: _____

telephone: _____ fax: _____

email: _____

Payment Options

Check payable to Venture Planning Group Please send me an invoice Please charge my credit card

card type: Visa MasterCard AMEX Other _____

cardholder's name: _____

card number: _____ expiration date: _____

signature: _____

